Results 241 to 250 of about 53,329 (292)
Some of the next articles are maybe not open access.
Phosphodiesterase 4 inhibitors
Journal of the American Academy of Dermatology, 2018Historically, drugs available for treating atopic dermatitis (AD) have been limited to topical corticosteroids and topical calcineurin inhibitors, with systemic immunosuppressants and phototherapy reserved for severe AD. Despite their efficacy and infrequent adverse events, phobia about the use of topical steroids and calcineurin inhibitors has limited
Rema, Zebda, Amy S, Paller
openaire +2 more sources
Electrophysiology of phosphodiesterase inhibitors
The American Journal of Cardiology, 1989Phosphodiesterase inhibitors appear to uniformly enhance atrioventricular node conduction, although milrinone seems to have the least effect. Except for digoxin, this effect on atrioventricular node conduction is similar to that noted with other inotropic agents.
G V, Naccarelli, R A, Goldstein
openaire +2 more sources
Xanthines and Phosphodiesterase Inhibitors
2016Theophylline is an orally acting xanthine that has been used since 1937 for the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). However, in most treatment guidelines, xanthines have now been consigned to third-line therapy because of their narrow therapeutic window and propensity for drug-drug ...
D, Spina, C P, Page
openaire +2 more sources
In Defense of Phosphodiesterase 5 Inhibitors
JAMA Ophthalmology, 2022Not ...
Belladelli, Federico +2 more
openaire +3 more sources
Phosphodiesterase-5 Inhibitors
2013Nitric oxide (NO) signaling plays a key role in modulating vascular tone and remodeling in the pulmonary circulation. The guanylate cyclase/cyclic guanylate monophosphate-signaling pathway primarily mediates nitric oxide signaling. This pathway is critical in normal regulation of the pulmonary vasculature, and is an important target for therapy in ...
Barbara A, Cockrill, Aaron B, Waxman
openaire +2 more sources
Phosphodiesterase inhibitors and lung diseases
2023Phosphodiesterase enzymes (PDE) have long been known as regulators of cAMP and cGMP, second messengers involved in various signaling pathways and expressed in a variety of cell types implicated in respiratory diseases such as airway smooth muscle and inflammatory cells making them a key target for the treatment of lung diseases as chronic obstructive ...
Ivana, Stolfa, Clive, Page
openaire +2 more sources
Phosphodiesterase inhibitors in psychiatric disorders
Psychopharmacology, 2023Challenges in drug development for psychiatric disorders have left much room for the introduction of novel treatments with better therapeutic efficacies and indices. As a result, intense research has focused on identifying new targets for developing such pharmacotherapies.
Mohammad Amin, Sadeghi +5 more
openaire +2 more sources
Chemotherapeutic potential of phosphodiesterase inhibitors
Current Opinion in Chemical Biology, 1998The application of molecular cloning has revealed the phenomenal diversity and complexity of the phosphodiesterase isoenzyme family. Thus, more than 30 human phosphodiesterases are now known; all are apparently necessary for the seemingly simple task of hydrolysing the 3'-ester bond of either cyclic adenosine monophosphate or cyclic guanosine ...
M J, Perry, G A, Higgs
openaire +2 more sources
2021
Cerebral ischemic diseases are among the most prevalent causes of death and the leading cause of adult disability worldwide. Although many studies have investigated the pathophysiological mechanisms involved in the cerebral ischemic injury, no effective pharmacological treatment has been established.
openaire +1 more source
Cerebral ischemic diseases are among the most prevalent causes of death and the leading cause of adult disability worldwide. Although many studies have investigated the pathophysiological mechanisms involved in the cerebral ischemic injury, no effective pharmacological treatment has been established.
openaire +1 more source
The new inotropic phosphodiesterase inhibitors
Archives Internationales de Physiologie et de Biochimie, 1984Compounds with phosphodiesterase inhibitory activity stimulate myocardial contractility by increasing the intracellular cyclic AMP concentrations. They can also increase Ca2+ entry and inhibit Ca2+ sequestration by the sarcoplasmic reticulum. Xanthines produce bronchodilation with associated venous and arteriolar dilation. However, their use is limited
D, el Allaf, V, D'Orio, J, Carlier
openaire +2 more sources